retatrutide mechanism glp-1 gip glucagon triple agonist review 2024 2025 Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing GLP-1-based therapies for type 2

Gastrointestinal, dermatologic, hematologic, renal, and immunologic manifestations have been reported

In addition, 67 participants (81.7%) reported reduced fatigue, 57 (69.5%) felt more energized, 36 (44%) noted clearer focus, and 41 (50%) demonstrated faster recovery and improved performance by the end of the study

ISSCR 2007, 2007

An analysis of six clinical trials found that AOD 9604 had a safety profile comparable to placebo and did not act through the IGF-1 pathway

injections are used in pregnancy only when the potential benefit clearly outweighs any theoretical risk

Whilst these effects might appear complementary, the combined hormonal and metabolic signalling could produce effects that are difficult to monitor or predict without clinical oversight